Imexpharm Corporation Share Price

Equities

IMP

VN000000IMP0

Pharmaceuticals

End-of-day quote Ho Chi Minh S.E. 03:30:00 20/06/2024 am IST 5-day change 1st Jan Change
74,400 VND +3.48% Intraday chart for Imexpharm Corporation +3.91% +31.45%

Financials

Sales 2024 * 2,19000Cr 8.76Cr 725.98Cr Sales 2025 * 2,48600Cr 9.94Cr 824.11Cr Capitalization 5,20800Cr 21Cr 1.73TCr
Net income 2024 * 33TCr 1.34Cr 110.89Cr Net income 2025 * 38TCr 1.53Cr 126.96Cr EV / Sales 2024 * 2.4 x
Net Debt 2024 * 5.7TCr 22.8L 19Cr Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.1 x
P/E ratio 2024 *
15.3 x
P/E ratio 2025 *
-
Employees 1,411
Yield 2024 *
-
Yield 2025 *
-
Free-Float 11.41%
More Fundamentals * Assessed data
Dynamic Chart
Imexpharm Corporation Appoints Tnrong Minh Hung, A Non-Executive Member of the Board of Directors, as A Member of the Audit Committee Under the Board of Directors CI
Imexpharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Imexpharm Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Imexpharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of Directors CI
Imexpharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Imexpharm Corporation Announces Dividend, Payable on October 20, 2023 CI
Imexpharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of Directors CI
Imexpharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Imexpharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Imexpharm Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Imexpharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Imexpharm Corporation announced that it has received funding from SK Group Ltd. CI
Imexpharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
1 day+3.48%
1 week+3.91%
Current month+9.25%
1 month+12.05%
3 months+8.93%
6 months+30.07%
Current year+31.45%
More quotes
1 week
69 600.00
Extreme 69600
74 400.00
1 month
65 800.00
Extreme 65800
74 400.00
Current year
56 500.00
Extreme 56500
74 400.00
1 year
52 100.00
Extreme 52100
74 400.00
3 years
41 428.57
Extreme 41428.5714
82 285.71
5 years
28 681.32
Extreme 28681.3187
82 285.71
10 years
20 076.54
Extreme 20076.5418
82 285.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 01/84/01
Chief Operating Officer 45 01/04/01
Corporate Secretary 41 01/08/01
Members of the board TitleAgeSince
Chief Executive Officer 72 01/84/01
Corporate Officer/Principal 51 01/98/01
Chief Operating Officer 45 01/04/01
More insiders
Date Price Change Volume
20/24/20 74,400 +3.48% 122,300
19/24/19 71,900 +2.57% 80,500
18/24/18 70,100 +0.14% 11,400
17/24/17 70,000 -0.57% 22,800
14/24/14 70,400 -1.68% 36,870

End-of-day quote Ho Chi Minh S.E., June 20, 2024

More quotes
Imexpharm Corporation is a Vietnam-based company engaged in the pharmaceutical industry. The Company manufactures, imports, exports and trades pharmaceutical products, antiseptics, traditional medicine, medical equipment and supplies, cosmetics, supplemental food and drinks. It is also involved in the provision of packaging services and warehousing services for pharmaceutical storage purposes. In addition, the Company is involved in medicinal herb cultivation.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
74,400 VND
Average target price
75,733 VND
Spread / Average Target
+1.79%
Consensus

Annual profits - Rate of surprise